Novartis' meningitis B vaccine wins breakthrough therapy status in U.S.

ZURICH Mon Apr 7, 2014 1:43am EDT

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013. REUTERS/Arnd Wiegmann

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013.

Credit: Reuters/Arnd Wiegmann

Related Topics

ZURICH (Reuters) - Novartis said U.S. health regulators have granted the Swiss drugmaker's meningitis B vaccine Bexsero breakthrough therapy status.

The Basel-based company in a statement on Monday said it plans to file for U.S. approval of Bexsero as early as the second quarter of this year.

Bexsero is widely seen as crucial to Novartis' vaccines business, which has struggled to catch market leaders GlaxoSmithKline, Sanofi and Merck. The business was the only one of Novartis' five divisions to report a full-year operating loss in 2013.

The vaccine already has approval in Europe, Canada and Australia and has been administered at several universities in the United States to stop outbreaks of meningitis across campuses.

(Reporting by Caroline Copley; Editing by Christopher Cushing)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (2)
BelieveInLove wrote:
Fantastic news! And all you need to do is put a second mortgage on your home, adopt a diet of ramen noodles, and sacrifice your kids future tuition to get it!

Apr 07, 2014 6:01am EDT  --  Report as abuse
BelieveInLove wrote:
Fantastic news! And all you need to do is put a second mortgage on your home, adopt a diet of ramen noodles, and sacrifice your kids future tuition to get it!

Apr 07, 2014 6:01am EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.